Panacea Life Sciences Holdings, Inc.
PLSH
$0.0539
$0.005912.29%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 55.93% | 195.72% | -5.00% | -14.99% | 45.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.93% | 195.72% | -5.00% | -14.99% | 45.23% |
| Cost of Revenue | 9.05% | 26.58% | -0.55% | -11.75% | 3.39% |
| Gross Profit | 21.72% | 18.85% | -0.90% | 10.28% | 13.04% |
| SG&A Expenses | -3.26% | 372.45% | 5.81% | -29.07% | -44.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.44% | 60.47% | 0.39% | -13.82% | -6.96% |
| Operating Income | 18.04% | -28.54% | -1.83% | 13.38% | 21.72% |
| Income Before Tax | 19.27% | -29.57% | 20.15% | 4.98% | 35.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.27% | -29.57% | 20.15% | 4.98% | 35.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.27% | -29.57% | 20.15% | 4.98% | 35.62% |
| EBIT | 18.04% | -28.54% | -1.83% | 13.38% | 21.72% |
| EBITDA | 22.31% | -42.29% | -4.02% | 20.05% | 29.13% |
| EPS Basic | 26.73% | -15.61% | 28.63% | 19.37% | 27.23% |
| Normalized Basic EPS | 18.15% | -12.90% | 18.00% | 31.11% | 13.07% |
| EPS Diluted | 26.73% | -15.61% | 28.63% | 19.37% | 27.23% |
| Normalized Diluted EPS | 18.15% | -12.90% | 18.00% | 31.11% | 13.07% |
| Average Basic Shares Outstanding | 10.21% | 12.08% | 11.81% | 17.91% | -11.53% |
| Average Diluted Shares Outstanding | 10.21% | 12.08% | 11.81% | 17.91% | -11.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
